June 2023 in “jurnal veteriner” The combination of Typhonium flagelliforme extract and natural interferons effectively reduces tumor growth in mice.
12 citations
,
February 2014 in “PLoS ONE” Topical rapamycin may effectively treat fibrous papules on the face.
March 2009 in “European Urology Supplements” February 2020 in “Oncology Times” Antibody drug conjugates show promise in targeting cancer cells while reducing harm to healthy cells.
February 2024 in “Journal of cutaneous and aesthetic surgery” The combined treatment helps improve severe hair loss and reduces the need for other medications.
December 2024 in “Journal of Medicinal Chemistry” A new topical treatment for hair loss shows promise by targeting androgen receptors.
August 2019 in “Journal of Invertebrate Pathology” Thymosin beta 4 protects cells from damage by blocking a harmful microRNA and boosting a protective gene.
June 2022 in “Frontiers in Immunology” Tofacitinib regrew hair in a man with total hair loss but raised cytokine levels, needing more research on possible side effects.
May 2025 in “Experimental Dermatology” Triphenylphosphine oxide can increase oil production and reduce inflammation in skin cells without affecting TRPM5.
26 citations
,
January 1992 in “Carcinogenesis” TPA strongly increases ODC activity in certain skin cells, potentially aiding tumor growth.
14 citations
,
August 2017 in “International Journal of Immunopathology and Pharmacology” Photodynamic therapy improved skin issues from sorafenib when other treatments failed.
12 citations
,
July 2012 in “Journal of cutaneous medicine and surgery” Adalimumab was safe but mostly ineffective for severe alopecia areata.
December 2007 in “대한피부과학회지” The treatment increased total hair count but wasn't significantly better than placebo.
March 2022 in “International Journal of Trichology” Tofacitinib may be effective for treating hair loss caused by alopecia areata that doesn't respond to other treatments.
2 citations
,
January 2022 in “JAAD Case Reports” The rash resolved after stopping ponatinib.
88 citations
,
July 2014 in “Journal of the American Academy of Dermatology” Targeted cancer therapies often cause skin reactions, so dermatologists must manage these effects.
14 citations
,
March 2015 in “Stem Cell Research & Therapy” ABCG2 protein marks stem-like skin cells in human epidermis.
1 citations
,
May 2025 in “Frontiers in Medicine” This retrospective case series evaluated the efficacy and safety of dual-targeted therapy (DTT) in 18 patients with refractory inflammatory bowel disease (IBD) across three tertiary hospitals in China. The study included 8 patients with ulcerative colitis and 10 with Crohn’s disease, using combinations of biologic agents and tofacitinib. Results showed high clinical response rates of 88.23% at 3 months, 91.67% at 6 months, and 100% at 9 months, with an endoscopic response in 88.89% of evaluated patients at 9 months. Adverse events were minimal, with some patients experiencing ustekinumab-associated arthralgia and alopecia, and tofacitinib-related allergic purpura, leading to a transition to monotherapy. Two patients developed infections but continued DTT after treatment. The study concludes that DTT is a promising and safe option for patients unresponsive to conventional monotherapies.
July 2012 in “European journal of cancer” MPA increases cancer spread by boosting Eph A2 activity.
5 citations
,
June 2001 in “Annals of Internal Medicine” Rituximab effectively treated a woman's bone lymphoma that was resistant to other treatments.
January 2010 in “Journal of Animal Science” Transcutaneous vaccination using nanoparticles can enhance immune responses and reduce basal cell carcinomas.
April 2023 in “Russian Journal of Clinical Dermatology and Venereology” Proteoglycan replacement therapy improved hair conditions in most patients with alopecia.
December 2025 in “Actas Dermo-Sifiliográficas” Ritlecitinib is effective and safe for treating severe alopecia areata in people aged 12 and older.
1 citations
,
July 2025 in “Journal of Photochemistry and Photobiology B Biology” Photobiomodulation helps protect hair follicle cells from damage caused by DHT.
16 citations
,
June 2018 in “JAAD case reports” A JAK inhibitor improved both severe hair loss and chronic skin disease in one patient.
20 citations
,
December 2021 in “Journal of the American Academy of Dermatology” Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.
1 citations
,
October 2021 in “Deleted Journal” Dupilumab can help regrow hair and improve skin conditions in patients with severe atopic dermatitis and alopecia areata.
508 citations
,
June 2009 in “Current drug metabolism” Tyrosine kinase inhibitors effectively treat cancers but often cause skin and other side effects.
9 citations
,
January 2015 in “Dermatology Online Journal” A patient with Crohn's disease grew back their hair after stopping Adalimumab, which had caused hair loss.
10 citations
,
August 2016 in “Oxford Medical Case Reports” Tocilizumab therapy may cause skin and hair conditions like halo naevi, vitiligo, and alopecia areata.